Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Estrogen is not recommended for menopausal hair loss due to insufficient evidence.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

In this study, Epimedii Folium extract was found to enhance melanin production and promote pigmentation through mechanisms involving the MAPK/ERK1/2 pathway in both in vitro and in vivo models.

In this study, estradiol was found to increase VEGF expression in cultured dermal papilla cells at physiological levels similar to pregnancy, suggesting that declining estrogen might contribute to female pattern hair loss in older Japanese women.

This study optimized efinaconazole spanlastic nanovesicles using risk management and multivariate analysis for potential transungual delivery to treat onychomycosis, achieving improved drug permeability and dissolution efficiency.

BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.

HA-iMSC-EVs can improve skin aging by boosting cell growth and restoring collagen and elastin.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This review examines the potential and challenges of extracellular vesicles in cosmetics, noting their transformative impact despite regulatory and production hurdles; it reports no new experimental results.

This article describes viDA Therapeutics Inc.'s focus on developing new drugs for age-related conditions using their proprietary granzyme-based approach but reports no clinical outcomes, primarily discussing their funding and business strategy.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

This review discusses the use of eflornithine cream for managing hirsutism in women and reports promising results from clinical experience but presents no new clinical trials.

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

This study found that epitestosterone acts as a weak antiandrogen by inhibiting receptor binding and 5α-reductase activity in animal models.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This review discusses the potential of adipose-derived stem cell extracellular vesicles (ADSC-EVs) in skin regeneration, highlighting mechanisms like inflammation and angiogenesis, but reports no new clinical results; challenges and future prospects are also considered.

This study found that the rs 1570360 polymorphism and the T-G-C haplotype of the VEGF gene may be associated with a protective factor against polycystic ovary syndrome in a Brazilian population.

This meeting review discusses recent advances in systemic psoriasis treatments, emphasizing the impact of dimethylfumarate monotherapy on understanding psoriasis and treatment strategies; it reports no new clinical results.

This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

This review concluded that for women, the benefits of testosterone implants are outweighed by risks, with possible higher rates of irreversible adverse effects than previously reported.

In this study, a combined therapy of nicotinamide and green tea polyphenols was reported to improve EGFR inhibitor-related skin toxicity and patient quality of life, suggesting it merits further investigation.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

In this study, researchers found that patients with psoriasis had a higher probability of achieving and maintaining a clinical response using brodalumab compared to ustekinumab over 52 weeks, as measured by a multistate modelling approach based on absolute PASI scores.

This review discusses the roles of extracellular vesicles in skin health and disease and reports no clinical results; the authors highlight potential therapeutic uses and call for more research.